Data from Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure
George D. Demetri(Dana-Farber Cancer Institute), Robert G. Maki(Memorial Sloan Kettering Cancer Center), Christopher D.�M. Fletcher(Brigham and Women's Hospital), Charles M. Baum(Brigham and Women's Hospital), Darrel P. Cohen, Ming Hui Chen(Boston Children's Hospital), Annick D. Van den Abbeele(Unknown), Suzanne George(Dana-Farber Cancer Institute), Carlo L. Bello, Cristina R. Antonescu(Memorial Sloan Kettering Cancer Center), Michael C. Heinrich(VA Portland Health Care System), Xin Huang, Jeffrey A. Morgan, Jonathan A. Fletcher(Harvard University), Christopher L. Corless(Oregon Health & Science University)
Cited by 0
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
|Journal of the National Comprehensive Cancer Network|2010|1.2k